Over the latest trailing 12-month period, total return cagr is +429.27%. The comparable SPY value is +16.94%. Year-to-date total return is -12.13%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Total Return CAGR averages 8.07% over 3 years and -25.05% over 5 years; the trailing 12 months came in at +429.27%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Damora Therapeutics, Inc. (DMRA)
Total Return growth vs the same calendar quarter one year earlier, last 21 comparable quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $5.39.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | -12.13% |
| 2025 | +394.84% |
| 2024 | -74.17% |
| 2023 | -37.39% |
| 2022 | -62.05% |
| 2021 | -75.78% |
| Period | Period End | QoQ Return | YoY Return |
|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | -2.1% | -12.1% |
| Q3 2026 | 2026-09-29 | -14.7% | +455.4% |
| Q2 2026 | 2026-06-29 | -0.2% | +610.0% |
| Q1 2026 | 2026-03-30 | +5.5% | +682.9% |
| Q4 2025 | 2025-12-31 | +518.5% | +394.8% |
| Q3 2025 | 2025-09-30 | +9.1% | -69.4% |
| Q2 2025 | 2025-06-30 | +10.0% | -71.2% |
| Q1 2025 | 2025-03-31 | -33.3% | -84.1% |
| Q4 2024 | 2024-12-31 | -61.7% | -74.2% |
| Q3 2024 | 2024-09-30 | +2.5% | -33.0% |
| Q2 2024 | 2024-06-28 | -39.2% | -81.2% |
| Q1 2024 | 2024-03-27 | +8.3% | -60.8% |
| Q4 2023 | 2023-12-29 | -0.7% | -37.4% |
| Q3 2023 | 2023-09-28 | -71.2% | -61.2% |
| Q2 2023 | 2023-06-30 | +26.6% | +37.0% |
| Q1 2023 | 2023-03-31 | +73.0% | -16.0% |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
